Rapport Therapeutics, Inc.
RAPP
$47.42
$0.060.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -185.11% | 41.19% | -25.40% | -0.72% | -11.09% |
| Total Depreciation and Amortization | -6.61% | -14.34% | 3.52% | 1.59% | 3.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.00% | 41.31% | -5.74% | 15.19% | 19.05% |
| Change in Net Operating Assets | 989.80% | -121.21% | -2.46% | 209.73% | -678.29% |
| Cash from Operations | -217.40% | 47.12% | -41.43% | 30.34% | -23.88% |
| Capital Expenditure | 9.30% | 49.11% | -26.12% | -509.09% | 92.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.98% | 121.84% | -207.47% | -350.43% | 6.08% |
| Cash from Investing | -32.53% | 121.76% | -207.04% | -351.27% | 7.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 96.79% | 160.13% | -99.89% | -- | -100.00% |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 33.70% | -- | -- | 200.00% | -- |
| Cash from Financing | 165.73% | 70.74% | -99.89% | 429,517.46% | -1,360.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -156.84% | 112.79% | -201.23% | 7,837.17% | -417.52% |